Heparin After Streptokinase
Unfractionated heparin (UFH) administration after streptokinase is optional (Class IIb recommendation), but when used, should be reserved for high-risk patients with large or anterior MI, atrial fibrillation, previous embolus, or known LV thrombus (Class I recommendation). 1, 2, 1
When to Initiate UFH After Streptokinase
The decision to use UFH after streptokinase differs fundamentally from fibrin-specific agents (alteplase, reteplase, tenecteplase), where UFH is mandatory. For streptokinase specifically:
High-Risk Patients (Class I - Definite Indication)
UFH should be given intravenously to patients with:
- Large or anterior MI
- Atrial fibrillation
- Previous embolic event
- Known left ventricular thrombus
These patients face elevated systemic embolic risk that justifies anticoagulation despite streptokinase's inherent anticoagulant effects from fibrin degradation products 1, 2, 1.
All Other Patients (Class IIb - Optional)
It may be reasonable to administer UFH intravenously to patients undergoing reperfusion with streptokinase, though the evidence is weaker (Level B) 1, 2, 1. The rationale: streptokinase activates both platelets and thrombin, creating prothrombotic effects that may warrant anticoagulation, but this must be balanced against bleeding risk 3.
Dosing Regimen
When UFH is used after streptokinase, administer:
- Bolus: 60 U/kg IV (maximum 4000 U)
- Infusion: 12 U/kg/hour (maximum 1000 U/hour for patients >70 kg)
- Target aPTT: 1.5 to 2.0 times control (approximately 50-70 seconds) 1, 4, 1, 2, 1
The European guidelines 4 provide identical dosing: 60 U/kg IV bolus with maximum 4000 U, followed by 12 U/kg/hour infusion for 24-48 hours, targeting aPTT 50-70 seconds or 1.5-2.0 times control, monitored at 3,6,12, and 24 hours.
Critical Timing Consideration
Do not initiate UFH until near the end of or immediately after streptokinase infusion completion 5. Starting heparin during streptokinase administration may increase bleeding risk without clear benefit.
Monitoring Parameters
aPTT Monitoring Protocol
- First check: 3 hours after starting infusion
- Subsequent checks: At 6,12, and 24 hours initially 4
- Ongoing: Every 4 hours during early treatment, then before each dose adjustment 6
- Target range: aPTT 1.5-2.0 times control (50-70 seconds) 1, 4, 1, 2, 1
Critical finding: Deviation from optimal aPTT at 12 hours post-initiation independently predicts recurrent MI (RR 9.01) and adverse outcomes (RR 3.24) at 30 days 7. Notably, excessive anticoagulation (aPTT >75 seconds) during the first 12 hours was associated with worse prognosis, not subtherapeutic levels 7.
Platelet Monitoring
Monitor platelet counts daily to screen for heparin-induced thrombocytopenia (HIT), particularly days 4-14 of therapy 1, 2, 1. HIT risk with UFH can reach 5% in certain populations 8.
Additional Safety Monitoring
- Periodic hematocrits
- Tests for occult blood in stool
- Clinical assessment for bleeding 6
Duration of Therapy
Continue UFH for minimum 48 hours, preferably for the duration of hospitalization, up to 8 days or until revascularization 9. Research supports that ≥4 days of IV heparin maintains infarct vessel patency better than shorter durations (100% vs 59% patency, p<0.05) 5.
Important Caveats and Pitfalls
The Subcutaneous Heparin Problem
Avoid fixed-dose subcutaneous heparin (12,500 U twice daily) without monitoring. This regimen, used in some large trials, produces marked individual variation with many patients inadequately anticoagulated and a circadian response pattern (median aPTT 48-52 seconds pre-dose, rising to 63-125 seconds post-dose) 10. This variability may explain heparin's apparent lack of benefit and increased hemorrhagic complications in certain trials 3.
Weight-Based Dosing is Essential
The measured effect of UFH on aPTT depends critically on patient weight 1, 2, 1. Fixed dosing without weight adjustment leads to unpredictable anticoagulation.
Streptokinase's Unique Pharmacology
Streptokinase produces fibrin degradation products with anticoagulant effects that may provide some protection against reocclusion 3. This differs from fibrin-specific agents and explains why UFH is less clearly beneficial after streptokinase compared to alteplase/reteplase/tenecteplase.
Consider Anti-Xa Monitoring
While aPTT remains standard, emerging evidence suggests anti-Xa assays (target 0.3-0.7 U/mL) provide more reliable monitoring, particularly in critically ill patients 11, 12. Anti-Xa assays are less affected by interferences and don't require local range determination 11.
Renal Dysfunction Considerations
For patients with significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women), LMWH should not be used as an alternative to UFH 1, 2, 1. UFH remains the safer parenteral option in this population.